{"id":"humira-adalimumab","safety":{"commonSideEffects":[{"rate":"12-15%","effect":"Injection site reactions"},{"rate":"7-10%","effect":"Upper respiratory tract infections"},{"rate":"5-8%","effect":"Headache"},{"rate":"<1%","effect":"Tuberculosis reactivation"},{"rate":"1-3%","effect":"Serious infections"},{"rate":"increased relative risk","effect":"Malignancy risk"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By blocking TNF-α, adalimumab reduces inflammatory signaling and immune activation in conditions driven by excessive TNF-α production. This leads to decreased inflammation, reduced immune cell infiltration, and suppression of disease progression in autoimmune and inflammatory disorders. TNF-α is a central mediator of inflammation in rheumatoid arthritis, psoriasis, inflammatory bowel disease, and other immune-mediated conditions.","oneSentence":"Adalimumab is a monoclonal antibody that binds to and neutralizes tumor necrosis factor-alpha (TNF-α), a key inflammatory cytokine.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:33:02.655Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Psoriatic arthritis"},{"name":"Ankylosing spondylitis"},{"name":"Crohn's disease"},{"name":"Ulcerative colitis"},{"name":"Plaque psoriasis"},{"name":"Hidradenitis suppurativa"},{"name":"Polyarticular juvenile idiopathic arthritis"}]},"trialDetails":[{"nctId":"NCT02840175","phase":"PHASE3","title":"Treatment Tapering in JIA With Inactive Disease","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2017-05-18","conditions":"Juvenile Idiopathic Arthritis","enrollment":62},{"nctId":"NCT07486843","phase":"PHASE4","title":"Preventing Structural Damage in Early Psoriatic Arthritis","status":"RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2026-03-16","conditions":"Psoriatic Arthritis (PsA)","enrollment":108},{"nctId":"NCT07147257","phase":"PHASE1","title":"A Trial to Assess the Pharmacokinetic Similarity Between CHS-1420 40 mg/0.4 mL and HUMIRA® (Adalimumab) 40 mg/0.4 mL in Healthy Chinese Adult Participants Under Fasting Conditions","status":"COMPLETED","sponsor":"Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd.","startDate":"2025-02-12","conditions":"Healthy Participants","enrollment":238},{"nctId":"NCT03412747","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"UCB Biopharma SRL","startDate":"2018-01-26","conditions":"Chronic Plaque Psoriasis, Moderate to Severe Plaque Psoriasis","enrollment":478},{"nctId":"NCT03895203","phase":"PHASE3","title":"A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis","status":"COMPLETED","sponsor":"UCB Biopharma SRL","startDate":"2019-04-03","conditions":"Psoriatic Arthritis","enrollment":852},{"nctId":"NCT02586831","phase":"PHASE1, PHASE2","title":"Diabetes Islet Preservation Immune Treatment","status":"WITHDRAWN","sponsor":"Camillo Ricordi and Jay Skyler","startDate":"2024-06-01","conditions":"Diabetes Mellitus, Type 1, Hypoglycemia, Autoimmune Diseases","enrollment":""},{"nctId":"NCT05633771","phase":"","title":"Observational Study, to Assess Treatment Retention of an Adalimumab Biosimilar (Hyrimoz®) in IBD Patients in Real Life Setting","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sandoz","startDate":"2023-02-16","conditions":"Inflammatory Bowel Disease","enrollment":562},{"nctId":"NCT02829424","phase":"PHASE4","title":"Multicenter Randomized Double Blind Controlled-study to Assess the Potential of Methotrexate Versus Placebo to Improve and Maintain Response to Anti TNF- Alpha Agents in Adult Patients With Moderate to Severe Psoriasis","status":"TERMINATED","sponsor":"Assistance Publique Hopitaux De Marseille","startDate":"2017-01-23","conditions":"Psoriasis","enrollment":78},{"nctId":"NCT05394805","phase":"","title":"A Study of Subcutaneous HUMIRA (Adalimumab) Injection to Assess Adverse Events and Change in Disease Activity In Adult Participants With Moderate to Severe Active Crohn's Disease (CD)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2022-06-29","conditions":"Crohn's Disease","enrollment":156},{"nctId":"NCT03104400","phase":"PHASE3","title":"A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-04-27","conditions":"Psoriatic Arthritis","enrollment":1705},{"nctId":"NCT07021495","phase":"","title":"SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2025-07-29","conditions":"Chronic Spontaneous Urticaria (CSU), Hidradenitis Suppurativa (HS), Psoriasis (PsO)","enrollment":840},{"nctId":"NCT03316781","phase":"PHASE3","title":"Study of Efficacy and Safety of HLX03 in Subjects With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Shanghai Henlius Biotech","startDate":"2017-10-27","conditions":"Plaque Psoriasis","enrollment":262},{"nctId":"NCT02130362","phase":"","title":"A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn's Disease (CD)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2014-08-28","conditions":"Crohn's Disease","enrollment":1446},{"nctId":"NCT01848561","phase":"","title":"A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2013-04-29","conditions":"Ulcerative Colitis (UC)","enrollment":8250},{"nctId":"NCT05108259","phase":"PHASE1","title":"To Compare the Pharmacokinetics and Safety of PBP1502 and Humira in Healthy Subjects","status":"RECRUITING","sponsor":"Prestige Biopharma Limited","startDate":"2022-03-30","conditions":"Healthy Volunteers","enrollment":324},{"nctId":"NCT03906136","phase":"PHASE3","title":"AScalate: Treat-to-target in Axial Spondyloarthritis","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2019-06-04","conditions":"Axial Spondyloarthritis","enrollment":304},{"nctId":"NCT05411211","phase":"","title":"An Observational Study to Assess Change in Disease Activity and Adverse Events of Adalimumab in Chinese Pediatric Participants With Polyarticular Juvenile Idiopathic Arthritis (pJIA)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2022-11-10","conditions":"Polyarticular Juvenile Idiopathic Arthritis","enrollment":20},{"nctId":"NCT06849908","phase":"PHASE2","title":"Baricitinib in the Treatment of Intestinal Behçet's Syndrome","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2024-11-08","conditions":"Behcet Syndrome, Intestinal Type","enrollment":56},{"nctId":"NCT04909801","phase":"PHASE3","title":"A Study to Compare the Response to Treatment With Abatacept vs Adalimumab, on Background Methotrexate, in Adults With Early, Seropositive, and Shared Epitope-positive Rheumatoid Arthritis and an Inadequate Response to Methotrexate","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2021-09-15","conditions":"Rheumatoid Arthritis","enrollment":338},{"nctId":"NCT00783510","phase":"","title":"Juvenile Idiopathic Arthritis (JIA) Registry","status":"COMPLETED","sponsor":"AbbVie","startDate":"2008-07-11","conditions":"Juvenile Idiopathic Arthritis, JIA","enrollment":849},{"nctId":"NCT05637515","phase":"PHASE3","title":"Hulio Interchangeability to Humira®, Comparing Pharmacokinetics, Efficacy, Safety and Immunogenicity","status":"COMPLETED","sponsor":"Biocon Biologics Inc.","startDate":"2022-11-21","conditions":"Moderate Chronic Plaque Psoriasis, Severe Chronic Plaque Psoriasis","enrollment":374},{"nctId":"NCT02451748","phase":"PHASE4","title":"IL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIA","status":"COMPLETED","sponsor":"University of Illinois at Chicago","startDate":"2015-08","conditions":"Rheumatoid Arthritis","enrollment":32},{"nctId":"NCT02634060","phase":"NA","title":"Home basEd faecaL calProtectin Measurements Predicting Adalimumab Induction Destiny","status":"COMPLETED","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2016-03-31","conditions":"Crohn Disease, Colitis, Ulcerative","enrollment":140},{"nctId":"NCT00799877","phase":"","title":"Chronic Plaque Psoriasis (Ps) Registry","status":"COMPLETED","sponsor":"AbbVie","startDate":"2008-09-26","conditions":"Chronic Plaque Psoriasis","enrollment":6065},{"nctId":"NCT06291948","phase":"PHASE1","title":"A Clinical Study With Adalimumab Biosimilar","status":"COMPLETED","sponsor":"Laboratorios Richmond S.A.C.I.F.","startDate":"2022-08-01","conditions":"Pharmacokinetics, Safety Issues","enrollment":150},{"nctId":"NCT04230213","phase":"PHASE3","title":"A Comparative Study Between PF-06410293 and Humira® in Combination With Methotrexate in Participants With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2020-01-13","conditions":"Rheumatoid Arthritis","enrollment":455},{"nctId":"NCT05073315","phase":"PHASE3","title":"A Comparative Study Between ABP 501 and Humira® in Participants With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Amgen","startDate":"2021-10-04","conditions":"Plaque Psoriasis","enrollment":425},{"nctId":"NCT02660580","phase":"PHASE3","title":"MSB11022 in Moderate to Severe Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"Fresenius Kabi SwissBioSim GmbH","startDate":"2016-02-16","conditions":"Psoriasis, Plaque Type Psoriasis, Moderate to Severe Plaque Psoriasis","enrollment":443},{"nctId":"NCT06005532","phase":"PHASE3","title":"Study Evaluation of the Efficacy, Safety and Immunogenicity of Adalimumab in Comparison With Humira®","status":"UNKNOWN","sponsor":"Mabscale, LLC","startDate":"2023-10-02","conditions":"Plaque Psoriasis","enrollment":494},{"nctId":"NCT03759288","phase":"PHASE2, PHASE3","title":"An Active and Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Crohn's Disease","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2018-12-07","conditions":"Crohn's Disease, IBD","enrollment":89},{"nctId":"NCT05995691","phase":"PHASE1","title":"Study to Determine the Pharmacokinetic (PK) Bioequivalence of ABP 501 and Adalimumab (Humira®) in Healthy Adult Japanese Participants","status":"COMPLETED","sponsor":"Amgen","startDate":"2014-11-24","conditions":"Healthy Volunteers","enrollment":179},{"nctId":"NCT04089514","phase":"","title":"A Real-world Study of Imraldi® Use","status":"COMPLETED","sponsor":"Biogen","startDate":"2019-06-30","conditions":"Arthritis, Rheumatoid (RA), Axial Spondyloarthritis (axSpA), Arthritis, Psoriatic (PsA)","enrollment":1000},{"nctId":"NCT02878083","phase":"NA","title":"Development of a Biomarker of Efficacy of Vedolizumab (EnTyvio®) in Patients With ulcErative ColiTis (DETECT)","status":"TERMINATED","sponsor":"Nantes University Hospital","startDate":"2017-01-11","conditions":"ULCERATIVE COLITIS","enrollment":19},{"nctId":"NCT03100253","phase":"PHASE4","title":"Rheumatoid Arthritis Treatment After First Anti-TNF INvestiGation","status":"TERMINATED","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2018-03-01","conditions":"Rheumatoid Arthritis","enrollment":208},{"nctId":"NCT05427942","phase":"","title":"Yuflyma® (Adalimumab), Patient Experience After Switching","status":"UNKNOWN","sponsor":"Celltrion HealthCare France","startDate":"2022-06-03","conditions":"Rheumatoid Arthritis, Ankylosing Spondylarthritis, Axial Spondyloarthritis Without Radiographic Evidence of Ankylosing Spondylitis","enrollment":300},{"nctId":"NCT03357939","phase":"PHASE1","title":"Phase I Study of HLX3 vs Adalimumab in Chinese Healthy Subjects","status":"COMPLETED","sponsor":"Shanghai Henlius Biotech","startDate":"2017-01-12","conditions":"Immune System Disorder","enrollment":220},{"nctId":"NCT03849313","phase":"PHASE1","title":"Pharmacokinetics, Safety and Tolerability Study of AVT02 to EU-approved and US-licensed Humira (Adalimumab)","status":"COMPLETED","sponsor":"Alvotech Swiss AG","startDate":"2019-03-20","conditions":"Healthy Volunteers","enrollment":390},{"nctId":"NCT04453137","phase":"PHASE3","title":"Pharmacokinetic, Efficacy, Safety, and Immunogenicity of AVT02 With Moderate to Severe Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"Alvotech Swiss AG","startDate":"2020-06-30","conditions":"Plaque Psoriasis","enrollment":567},{"nctId":"NCT03248531","phase":"PHASE2","title":"A Study to Test the Efficacy, Safety and Pharmacokinetics of Bimekizumab in Subjects With Moderate to Severe Hidradenitis Suppurativa.","status":"COMPLETED","sponsor":"UCB Biopharma SRL","startDate":"2017-09-22","conditions":"Hidradenitis Suppurativa","enrollment":90},{"nctId":"NCT02714322","phase":"PHASE3","title":"MYL-1401A Efficacy and Safety Comparability Study to Humira®","status":"COMPLETED","sponsor":"Mylan Inc.","startDate":"2015-06","conditions":"Psoriasis, Arthritis, Psoriatic","enrollment":294},{"nctId":"NCT05190484","phase":"","title":"bIosimilar of aDalimumab, an European evAluation","status":"UNKNOWN","sponsor":"Fresenius Kabi","startDate":"2022-04-30","conditions":"Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis","enrollment":1050},{"nctId":"NCT02916017","phase":"","title":"HUMIRA® Long-term Treatment in Patients With Non-infectious Intermediate-, Posterior-, or Pan-uveitis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-11-15","conditions":"Uveitis","enrollment":259},{"nctId":"NCT00837434","phase":"PHASE4","title":"Anti-TNF Agents for the Treatment of Rheumatoid Arthritis","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2009-03","conditions":"Rheumatoid Arthritis","enrollment":63},{"nctId":"NCT02762955","phase":"PHASE3","title":"Comparative Clinical Trial of Efficacy and Safety of BCD-057 and Humira® in Patients With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Biocad","startDate":"2016-12","conditions":"Psoriasis","enrollment":344},{"nctId":"NCT03383263","phase":"","title":"A Study to Assess Persistence, Adherence and Changes in Disease Activity in the Children Population of Juvenile Arthritis Patients Treated With Adalimumab (HUMIRA®)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2018-05-04","conditions":"Polyarticular Juvenile Arthritis","enrollment":70},{"nctId":"NCT02207231","phase":"PHASE3","title":"A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-11-26","conditions":"Psoriasis","enrollment":837},{"nctId":"NCT02207244","phase":"PHASE3","title":"A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis With Randomized Withdrawal and Retreatment","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-11-03","conditions":"Psoriasis","enrollment":992},{"nctId":"NCT03339102","phase":"","title":"Post-marketing Surveillance Study of Adalimumab (Humira®) for Non-infectious Intermediate, Posterior, or Panuveitis Patients","status":"COMPLETED","sponsor":"AbbVie","startDate":"2018-01-25","conditions":"Non-infectious Intermediate, Posterior and Panuveitis","enrollment":158},{"nctId":"NCT03210259","phase":"PHASE3","title":"The VOLTAIRE-X Trial Looks at the Effect of Switching Between Humira® and BI 695501 in Patients With Plaque Psoriasis","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2017-07-10","conditions":"Psoriasis","enrollment":259},{"nctId":"NCT04045782","phase":"PHASE4","title":"Evaluation of the Safety and Effectiveness of Switching From Humira® to Imraldi® in Flanders","status":"COMPLETED","sponsor":"Pieter Dewint, MD PhD","startDate":"2019-08-19","conditions":"Inflammatory Bowel Diseases","enrollment":130},{"nctId":"NCT02746380","phase":"PHASE3","title":"A Study Comparing LBAL to Humira® in Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy","status":"COMPLETED","sponsor":"LG Life Sciences","startDate":"2016-04-13","conditions":"Arthritis, Rheumatoid","enrollment":383},{"nctId":"NCT03311464","phase":"PHASE3","title":"A Study Assessing the Efficacy and Safety of Adalimumab in Active Ulcer(s) of Pyoderma Gangrenosum in Participants in Japan","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-10-27","conditions":"Pyoderma Gangrenosum","enrollment":22},{"nctId":"NCT03155243","phase":"","title":"Impact of Humira® Therapy on Ocular Inflammation, Selected Health Care Resource Utilization and Patient Reported Outcomes in Patients With Active Non-infectious Intermediate, Posterior and Panuveitis in Routine Clinical Practice","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-06-20","conditions":"Uveitis","enrollment":155},{"nctId":"NCT03172325","phase":"PHASE3","title":"Study to Demonstrate Non-Inferior Efficacy and Safety of CinnoRA® Versus Humira® for Treatment of Active RA","status":"COMPLETED","sponsor":"Cinnagen","startDate":"2015-11-18","conditions":"Active Rheumatoid Arthritis","enrollment":136},{"nctId":"NCT03927352","phase":"PHASE3","title":"The Purpose of This Research Study is to Compare the Efficacy and Safety of SCT630 and Adalimumab (HUMIRA®) in Adults With Plaque Psoriasis","status":"UNKNOWN","sponsor":"Sinocelltech Ltd.","startDate":"2019-09-05","conditions":"Psoriasis","enrollment":330},{"nctId":"NCT01764321","phase":"","title":"Noninterventional Examination of Subcutaneous (sc) Tumor Necrosis Factor (TNF) Inhibitors","status":"COMPLETED","sponsor":"UCB Pharma SA","startDate":"2012-12","conditions":"Rheumatoid Arthritis","enrollment":1723},{"nctId":"NCT03017014","phase":"","title":"A Study to Assess Safety and Effectiveness of Adalimumab for Treating Children and Adolescents With Crohn's Disease in Real Life Conditions","status":"TERMINATED","sponsor":"AbbVie","startDate":"2017-09-26","conditions":"Crohn's Disease","enrollment":62},{"nctId":"NCT02988674","phase":"","title":"A Study to Assess Retention Rate, Persistence and Adherence in Population of Spondylarthritis (Ankylosing Spondylitis and Psoriatic Arthritis) Patients Treated With Adalimumab in Routine Clinical Settings in Russian Federation","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-12-22","conditions":"Spondylarthritis, Psoriatic Arthritis, Ankylosing Spondylitis (AS)","enrollment":139},{"nctId":"NCT04422171","phase":"","title":"A 12-month Real Life Study of IBD Patients Switched From Adalimumab Originator Humira® to One of Its Biosimilar","status":"UNKNOWN","sponsor":"University Hospital, Grenoble","startDate":"2020-06-19","conditions":"IBD Patients, Originator Treatment, Biosimilar, Switch Back","enrollment":400},{"nctId":"NCT03849404","phase":"PHASE3","title":"Efficacy, Safety, and Immunogenicity of AVT02 With Moderate-to-Severe Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"Alvotech Swiss AG","startDate":"2019-02-20","conditions":"Plaque Psoriasis","enrollment":413},{"nctId":"NCT04439929","phase":"PHASE1","title":"Comparative Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of Adalimumab in Healthy Subjects","status":"COMPLETED","sponsor":"Turgut İlaçları A.Ş.","startDate":"2019-07-17","conditions":"Healthy Participants","enrollment":168},{"nctId":"NCT03001115","phase":"","title":"Post-Marketing Surveillance of Adalimumab in Korean Hidradenitis Suppurativa Subjects","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-03-10","conditions":"Hidradenitis Suppurativa (HS)","enrollment":17},{"nctId":"NCT02871635","phase":"PHASE3","title":"BI 695501 Versus Humira in Patients With Active Crohn's Disease: a Trial Comparing Efficacy, Endoscopic Improvement, Safety, and Immunogenicity","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2016-09-28","conditions":"Crohn Disease","enrollment":147},{"nctId":"NCT02896920","phase":"","title":"Canadian Humira Post Marketing Observational Epidemiological Study : Assessing Humira Real-life Effectiveness and Impact on HS Burden of Illness","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-09-20","conditions":"Hidradenitis Suppurativa (HS)","enrollment":165},{"nctId":"NCT03223012","phase":"","title":"Impact of AbbVie Care Patient Support Program on Clinical, Health Economic and Patient Reported Outcomes, in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriatic Arthritis, Psoriasis and Axial Spondyloarthritis, in the Portuguese National Health Service","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-11-15","conditions":"Crohn's Disease, Ulcerative Colitis (UC), Rheumatoid Arthritis (RA)","enrollment":116},{"nctId":"NCT04147026","phase":"NA","title":"Prediction Medical Device for Rheumatoid Arthritis (PREDIRA)","status":"UNKNOWN","sponsor":"Hospital San Carlos, Madrid","startDate":"2019-12-16","conditions":"Arthritis, Rheumatoid","enrollment":180},{"nctId":"NCT03016260","phase":"","title":"RABIOPRED - a Validation Study of Theranostic Test to PREDict Treatment Response of Anti-TNFα BIologicals in Rheumatoid Arthritis","status":"TERMINATED","sponsor":"TcLand Expression S.A.","startDate":"2016-12","conditions":"RheumatoId Arthritis","enrollment":250},{"nctId":"NCT03052322","phase":"PHASE3","title":"MSB11022 in Moderate to Severe Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Fresenius Kabi SwissBioSim GmbH","startDate":"2017-01-31","conditions":"Moderate to Severe Rheumatoid Arthritis","enrollment":288},{"nctId":"NCT03258814","phase":"","title":"A Post-Marketing-Observational Study (PMOS) to Determine the Effectiveness of Combined Adalimumab Treatment and Active Supervised Training in Patients With Axial Spondyloarthritis (axSpA)","status":"TERMINATED","sponsor":"AbbVie","startDate":"2017-12-08","conditions":"Axial Spondyloarthritis","enrollment":17},{"nctId":"NCT01412021","phase":"","title":"Special Investigation (All Case Survey) in Patients With Juvenile Idiopathic Arthritis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2011-07-01","conditions":"Arthritis, Juvenile Rheumatoid","enrollment":375},{"nctId":"NCT01078558","phase":"","title":"A Belgian Registry of HUMIRA® (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis ( ProAct )","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2004-05-13","conditions":"Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis","enrollment":5940},{"nctId":"NCT03014947","phase":"PHASE1","title":"MSB11022 in Healthy Subjects","status":"COMPLETED","sponsor":"Fresenius Kabi SwissBioSim GmbH","startDate":"2014-05","conditions":"Healthy Subjects","enrollment":237},{"nctId":"NCT01464333","phase":"","title":"Special Investigation (Long-term Investigation) in Patients With Crohn's Disease","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2011-12-16","conditions":"Crohn's Disease","enrollment":511},{"nctId":"NCT01947816","phase":"","title":"Special Investigation in Patients With Ulcerative Colitis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2013-08-09","conditions":"Ulcerative Colitis","enrollment":1621},{"nctId":"NCT01970488","phase":"PHASE3","title":"Study to Compare Efficacy and Safety of ABP 501 and Adalimumab (HUMIRA®) in Adults With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Amgen","startDate":"2013-10-18","conditions":"Psoriasis","enrollment":350},{"nctId":"NCT02405780","phase":"PHASE3","title":"A Study to Compare FKB327 Long-term Safety, Efficacy and Immunogenicity With Humira® in Rheumatoid Arthritis Patients","status":"COMPLETED","sponsor":"Fujifilm Kyowa Kirin Biologics Co., Ltd.","startDate":"2015-06-10","conditions":"Arthritis, Rheumatoid","enrollment":645},{"nctId":"NCT01960790","phase":"","title":"Special Investigation in Patients With Intestinal Behcet's Disease (All Case Investigation)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2013-05-25","conditions":"Behcet's Disease","enrollment":473},{"nctId":"NCT02850965","phase":"PHASE3","title":"Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2016-08-17","conditions":"Psoriasis","enrollment":318},{"nctId":"NCT01076205","phase":"","title":"Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2009-01-12","conditions":"Rheumatoid Arthritis","enrollment":7229},{"nctId":"NCT03827876","phase":"PHASE4","title":"Enstilar in Combination With Enbrel or Humira for Plaque Psoriasis","status":"RECRUITING","sponsor":"Psoriasis Treatment Center of Central New Jersey","startDate":"2019-01-16","conditions":"Psoriasis","enrollment":30},{"nctId":"NCT02480153","phase":"PHASE3","title":"A Study Of PF-06410293 (Adalimumab-Pfizer) And Adalimumab (Humira®) In Combination With Methotrexate In Subjects With Active Rheumatoid Arthritis (REFLECTIONS B538-02).","status":"COMPLETED","sponsor":"Pfizer","startDate":"2015-06-25","conditions":"Rheumatoid Arthritis","enrollment":597},{"nctId":"NCT03579823","phase":"PHASE1","title":"Comparative Safety, Tolerability, Pharmacokinetic Study of AVT02 (100MG/ML) and Humira (100MG/ML) in Healthy Volunteers","status":"COMPLETED","sponsor":"Alvotech Swiss AG","startDate":"2018-05-21","conditions":"Healthy Volunteers","enrollment":24},{"nctId":"NCT02744755","phase":"PHASE3","title":"Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Sandoz","startDate":"2016-03-31","conditions":"Rheumatoid Arthritis","enrollment":353},{"nctId":"NCT02578238","phase":"","title":"Post-Marketing Surveillance of Humira in Korean Pediatric Crohn's Disease (CD) Patients Under the \"New-Drug Re-examination\"","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-09-24","conditions":"Pediatric Crohn's Disease","enrollment":143},{"nctId":"NCT03254810","phase":"PHASE1","title":"Comparison of the Safety and PK of SYN060 to Humira® in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Synermore Biologics Co., Ltd.","startDate":"2017-09-26","conditions":"Arthritis, Rheumatoid","enrollment":94},{"nctId":"NCT02144714","phase":"PHASE1","title":"Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of SB5 in Healthy Subjects","status":"COMPLETED","sponsor":"Samsung Bioepis Co., Ltd.","startDate":"2014-05","conditions":"Healthy","enrollment":189},{"nctId":"NCT02581345","phase":"PHASE3","title":"Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis","status":"COMPLETED","sponsor":"Momenta Pharmaceuticals, Inc.","startDate":"2015-09","conditions":"Chronic Plaque Psoriasis, Psoriasis","enrollment":572},{"nctId":"NCT03273192","phase":"PHASE1","title":"A Study Of CinnoRA (Adalimumab-CinnaGen) And Adalimumab (Humira) In Healthy Subjects","status":"COMPLETED","sponsor":"Cinnagen","startDate":"2016-10-22","conditions":"Bioequivalence, Phase 1","enrollment":74},{"nctId":"NCT01550965","phase":"PHASE3","title":"A Study to Evaluate the Impact of Adalimumab on Quality of Life, Health Care Utilization and Costs of Ulcerative Colitis Subjects in the Usual Clinical Practice Setting","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2012-05","conditions":"Ulcerative Colitis","enrollment":463},{"nctId":"NCT01927757","phase":"PHASE4","title":"Evaluating Etanercept Use in Patients With Moderate to Severe Rheumatoid Arthritis Who Have Lost Response to Adalimumab","status":"TERMINATED","sponsor":"Amgen","startDate":"2013-05-06","conditions":"Moderate to Severe Rheumatoid Arthritis","enrollment":90},{"nctId":"NCT02137226","phase":"PHASE3","title":"BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2015-01-26","conditions":"Arthritis, Rheumatoid","enrollment":645},{"nctId":"NCT01543204","phase":"PHASE4","title":"Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab","status":"TERMINATED","sponsor":"Amgen","startDate":"2012-02-01","conditions":"Psoriasis","enrollment":64},{"nctId":"NCT02260791","phase":"PHASE3","title":"A Study to Compare FKB327 Efficacy and Safety With Humira® in Rheumatoid Arthritis Patients","status":"COMPLETED","sponsor":"Fujifilm Kyowa Kirin Biologics Co., Ltd.","startDate":"2014-12","conditions":"Arthritis, Rheumatoid","enrollment":728},{"nctId":"NCT02019472","phase":"PHASE3","title":"A Study Comparing Sirukumab (CNTO 136) Monotherapy With Adalimumab (HUMIRA®) Monotherapy in the Treatment of Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-04-04","conditions":"Arthritis, Rheumatoid","enrollment":559},{"nctId":"NCT02167139","phase":"PHASE3","title":"A Study Comparing SB5 to Humira® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy","status":"COMPLETED","sponsor":"Samsung Bioepis Co., Ltd.","startDate":"2014-05","conditions":"Rheumatoid Arthritis","enrollment":544},{"nctId":"NCT02016105","phase":"PHASE3","title":"Study to Demonstrate Equivalent Efficacy and to Compare Safety of Biosimilar Adalimumab (GP2017) and Humira","status":"COMPLETED","sponsor":"Sandoz","startDate":"2013-12","conditions":"Plaque Type Psoriasis","enrollment":465},{"nctId":"NCT01674413","phase":"PHASE3","title":"Calprotectin-Directed Humira® Maintenance Therapy (CADHUM)","status":"WITHDRAWN","sponsor":"Peter Higgins","startDate":"2013-10","conditions":"Crohn's Disease","enrollment":""},{"nctId":"NCT01346488","phase":"","title":"Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2011-06","conditions":"Rheumatoid Arthritis","enrollment":2088},{"nctId":"NCT01083680","phase":"","title":"Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2007-05","conditions":"Crohn's Disease","enrollment":4107},{"nctId":"NCT01756235","phase":"","title":"Physical Activity in Patients With Rheumatoid Arthritis Treated With Adalimumab in Routine Clinical Practice","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2012-12","conditions":"Rheumatoid Arthritis","enrollment":462}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["ABT-D2E7","adalimumab","Humira"],"phase":"marketed","status":"active","brandName":"Humira® (Adalimumab)","genericName":"Humira® (Adalimumab)","companyName":"Mylan Inc.","companyId":"mylan-inc","modality":"Biologic","firstApprovalDate":"","aiSummary":"Adalimumab is a monoclonal antibody that binds to and neutralizes tumor necrosis factor-alpha (TNF-α), a key inflammatory cytokine. Used for Rheumatoid arthritis, Psoriatic arthritis, Ankylosing spondylitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}